June 11, 2026
1 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
FDA approves bimonthly dosing regimen for Ebglyss in adults, children with eczema
The FDA approved a regimen of one maintenance dose every 8 weeks for lebrikizumab-lbkz in adults and children aged 12 years and older who weigh at least 88 pounds with moderate to severe atopic dermatitis, according to a press release. Lebrikizumab-lbkz (Ebglyss, Eli Lilly) 250 mg/2 mL single injection, a targeted interleukin-13 inhibitor, is already approved for a once-monthly maintenance dose.
745 words~3 min read
